Structure Therapeutics (GPCR) Net Cash Flow (2022 - 2026)

Structure Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$483.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 2680.55% year-over-year to -$483.5 million in Q1 2026; TTM through Mar 2026 was $164.0 million, a 202.16% increase from a year earlier, with the FY2025 full-year figure at $630.1 million, up 1486.47% from the prior year.
• Net Cash Flow slipped to -$483.5 million in Q1 2026 per GPCR's latest filing, from $696.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $696.7 million in Q4 2025 and bottomed at -$483.5 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$5.1 million (2025), against an average of $12.4 million.
• Across the five-year window, Net Cash Flow jumped 26692.02% in 2025 and sank 2680.55% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$2.0 million in 2022, then surged by 4055.82% to $79.2 million in 2023, then slumped by 103.31% to -$2.6 million in 2024, then soared by 26692.02% to $696.7 million in 2025, then tumbled by 169.39% to -$483.5 million in 2026.
• Per Business Quant, the three latest GPCR Net Cash Flow figures stand at -$483.5 million (Q1 2026), $696.7 million (Q4 2025), and -$44.1 million (Q3 2025).